Currently in the midst of a strategic redeployment, Quantum Genomics announced last night that it had entered into advanced discussions with a company whose skills complement its own.

The biopharmaceutical company had already announced, at the end of 2022, that it had entered into discussions with several companies in order to build a 'new business project'.

Its efforts have focused on projects already in the commercialization phase or close to market launch, operating in volume markets and with high technological value in the healthcare sector.

Within the framework of the discussions underway with its potential partner, the aim is to reach an agreement in the short term, states Quantum in a press release.

The company explains that it has restructured and significantly lowered its fixed cost structure in order to launch its new start 'under the best possible conditions'.

At the end of October, the company had announced negative results from its Phase III study, prompting it to take the decision to halt another Phase II study, as well as all related developments.

Following the formalization of these discussions, Quantum shares climbed by over 70% on Thursday on the Paris Bourse.

Copyright (c) 2023 CercleFinance.com. All rights reserved.